The GAS6/AXL complex has been shown to stabilize β-catenin in human CML CD4+ cells, presenting a potential target for eliminating CML LSCs.107 Therefore, targeting AXL or its signaling pathways may enhance clinical response to anticancer therapies by reducing stemness, recurrence and metastasis. Here, AXL is linked to chronic myelogenous leukemia, BCR-ABL1 positive.